Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
61 hedge funds and large institutions have $87.6M invested in Oyster Point Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 21 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 72 → 61 (-11)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
64% less capital invested
Capital invested by funds: $246M → $87.6M (-$159M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$1.96M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$1.2M |
| 3 |
Millennium Management
New York
|
+$765K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$668K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.18M |
| 2 |
First Manhattan
New York
|
-$3.03M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.76M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.25M |
| 5 |
State Street
Boston,
Massachusetts
|
-$868K |
OYST Hedge Fund Activity: Q2 2022 in Review
61 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q2 2022, worth a combined $87.6M — down 64% from $246M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OYST and 11 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $1.96M. The largest seller was BlackRock, cutting an estimated $3.18M.
- 61 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q2 2022, down from 72 in Q1 2022.
- Funds reported $87.6M of Oyster Point Pharma, Inc. Common Stock stock for Q2 2022, down 64% quarter-over-quarter.
- 11 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q2 2022 and 21 closed out, a net change of -10 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q2 2022 was Paradigm Biocapital Advisors, an estimated $1.96M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.18M sold.
Based on aggregated 13F filings for Q2 2022.